Raymond E. Meyn

8.5k citations

135 papers · 7.0k indexed · h-index 49

Cancer Research top 1%
- Carcinogens and Genotoxicity Assessment 12
Oncology top 1%
- Cancer-related Molecular Pathways 33
Molecular Biology top 1%
- DNA Repair Mechanisms 30
- Cell death mechanisms and regulation 21
- DNA and Nucleic Acid Chemistry 10
Biotechnology top 1%
- Cancer Research and Treatments 16
Otorhinolaryngology top 5%
Genetics
- Virus-based gene therapy research 11
Radiology, Nuclear Medicine and Imaging
- Effects of Radiation Exposure 10

Co-authors: Anupama Munshi L. Clifton Stephens Marvette L. Hobbs David Murray Luka Milas Clifton C. Ling William C. Dewey David Voehringer
Cited by: Cancer Research Oncology Molecular Biology
Journals: Radiation Research (14 papers)International Journal of Radiation Oncology*Biology*Physics (13 papers)Clinical Cancer Research (9 papers)
Partner nations: United States Italy China

In The Last Decade

Raymond E. Meyn

135 papers receiving 6.8k citations

Peers

Countries citing papers authored by Raymond E. Meyn

Since Specialization

Citations

This map shows the geographic impact of Raymond E. Meyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond E. Meyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond E. Meyn more than expected).

Fields of papers citing papers by Raymond E. Meyn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond E. Meyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond E. Meyn. The network helps show where Raymond E. Meyn may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Raymond E. Meyn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Raymond E. Meyn Line = papers co-authored together Raymond E. Meyn links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade Cancer Research ·David Molkentine,Jessica M. Molkentine,Kathleen A. Bridges,David R. Valdecanas,B. Copin,Anita Scigliano,Yinet Torres-Peña,Manish Kumar,Liangpeng Yang,山中愼介,Phillip M. Pifer,Vlad C. Sandulache,Aakash Sheth,Beth M. Beadle,Howard D. Thames,Kathryn A. Mason,Curtis R. Pickering,Raymond E. Meyn,Heath D. Skinner	2021	22
2	BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer Clinical Cancer Research ·Tara Beth Davis,Manish Kumar,Liangpeng Yang,David Molkentine,David R. Valdecanas,Shiying Yu,Raymond E. Meyn,John V. Heymach,Heath D. Skinner	2017	20
3	Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer Clinical Cancer Research ·Heath D. Skinner,Uma Giri,Liang Yang,Manish Kumar,Ying Liu,Michael D. Story,Curtis R. Pickering,Lauren A. Byers,Michelle D. Williams,Jing Wang,Li Shen,Suk Young Yoo,You Hong Fan,David Molkentine,Beth M. Beadle,Raymond E. Meyn,Jeffrey N. Myers,John V. Heymach	2017	86
4	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer Clinical Cancer Research ·Heath D. Skinner,Uma Giri,Liang Yang,Sang Hyeok Woo,Michael D. Story,Curtis R. Pickering,Lauren A. Byers,Michelle D. Williams,Adel K. El‐Naggar,Jing Wang,Lixia Diao,Li Shen,You Hong Fan,David Molkentine,Beth M. Beadle,Raymond E. Meyn,Jeffrey N. Myers,John V. Heymach	2016	55
5	Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model Molecular Cancer Therapeutics ·Vlad C. Sandulache,Yunyun Chen,Heath D. Skinner,Christine Künzel,Lei Feng,Laurence E. Court,Jeffrey N. Myers,Raymond E. Meyn,Clifton D. Fuller,James A. Bankson,Stephen Y. Lai	2015	16
6	Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence Molecular Cancer Therapeutics ·Abdullah A. Osman,Marcus M. Monroe,Marcus V. Ortega Alves,Ameeta A. Patel,Panagiotis Katsonis,Alison L. Fitzgerald,David M. Neskey,Mitchell J. Frederick,Sang Hyeok Woo,Carlos Caulı́n,Muath K. Alsheik,Thomas O. McDonald,Marek Kimmel,Raymond E. Meyn,Olivier Lichtarge,Jeffrey N. Myers	2014	88
7	Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer Molecular Therapy ·María Angélica Cortez,David R. Valdecanas,Xiaochun Zhang,Yanai Zhan,Vikas Bhardwaj,George A. Călin,Ritsuko Komaki,Dipak Kumar Giri,Caio C. Quini,Tatiana Wolfe,Heidi J. Peltier,Andreas G. Bader,John V. Heymach,Raymond E. Meyn,James W. Welsh	2014	162
8	Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer Radiation Oncology ·P. Reiser,Tommy Sheu,Kathleen A. Bridges,Kathy A. Mason,Deborah A. Kuban,Paul Mathew,Raymond E. Meyn	2012	35
9	MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells Clinical Cancer Research ·Kathleen A. Bridges,Hiroshi Hirai,Carolyn A. Buser,P. Reiser,Huifeng Liu,Thomas A. Buchholz,Jessica M. Molkentine,Kathryn A. Mason,Raymond E. Meyn	2011	185
10	TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence Clinical Cancer Research ·Heath D. Skinner,Vlad C. Sandulache,Thomas J. Ow,Raymond E. Meyn,John S. Yordy,Beth M. Beadle,Alison L. Fitzgerald,Uma Giri,K. Kian Ang,Jeffrey N. Myers	2011	222
11	Radiosensitization of human melanoma cells by sorafenib (BAY 43-9006), a multi-kinase inhibitor Cancer Research ·Anupama Munshi,Toshimitsu Tanaka,Marvette L. Hobbs,Raymond E. Meyn	2006	1
12	Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation Cancer Gene Therapy ·Charles J. Rosser,Motoyoshi Tanaka,Louis L. Pisters,Yousefali Attari,Lawrence B. Levy,Raquel Engel,H. Barton Grossman,Timothy J. McDonnell,Deborah A. Kuban,Raymond E. Meyn	2004	52
13	Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation Molecular Therapy ·Takashi Nishikawa,Rajagopal Ramesh,Anupama Munshi,Sunil Chada,Raymond E. Meyn	2004	87
14	Environmental carcinogens and p53 tumor‐suppressor gene interactions in a transgenic mouse model for mammary carcinogenesis Environmental and Molecular Mutagenesis ·Daniel Medina,Robert L. Ullrich,Raymond E. Meyn,Roger W. Wiseman,L A Donehower	2002	18
15	The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange Carcinogenesis ·James B. Wilson,Mark Johnson,Mohamed Amin,Douglas Richard Anthony,Simon May,Peter E. Bryant,Raymond E. Meyn,Alan D. D’Andrea,Nigel J. Jones	2001	36
16	Protease inhibitors restore radiation‐induced apoptosis to Bcl‐2‐expressing lymphoma cells International Journal of Cancer ·John F. Kurland,Raymond E. Meyn	2001	38
17	Adenovirus-mediated p16INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner Oncogene ·Shinichiro Kawabe,Jack A. Roth,Debra Rose Wilson,Raymond E. Meyn	2000	35
18	Radiation-induced tumorigenesis in preneoplastic mouse mammary glands in vivo: Significance ofp53 status and apoptosis Molecular Carcinogenesis ·Daniel Medina,L. Clifton Stephens,Pedro J. Bonilla,Christiane Hollmann,Denise J. Schwahn,Charlotte Kuperwasser,D. Joseph Jerry,Janet S. Butel,Raymond E. Meyn	1998	13
19	Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol Cancer Chemotherapy and Pharmacology ·Luka Milas,Nancy Hunter,Belma Kurdoglu,Kathryn A. Mason,Raymond E. Meyn,L. Clifton Stephens,Lester J. Peters	1995	157
20	Radiation biology in cancer research : [proceedings] Raven Press eBooks ·Raymond E. Meyn,H. Rodney Withers	1980	1

About Raymond E. Meyn

Raymond E. Meyn is a scholar working on Oncology, Biotechnology, Cancer Research, Molecular Biology and Biophysics, having authored 135 papers that have together received 7.0k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (33 papers), DNA Repair Mechanisms (30 papers), Cell death mechanisms and regulation (21 papers), Cancer Research and Treatments (16 papers), Carcinogens and Genotoxicity Assessment (12 papers), Virus-based gene therapy research (11 papers), DNA and Nucleic Acid Chemistry (10 papers) and Effects of Radiation Exposure (10 papers). The work is most often cited by research in Cancer Research (1.6k citations), Oncology (2.5k citations), Molecular Biology (4.5k citations), Biotechnology (488 citations) and Otorhinolaryngology (137 citations). Raymond E. Meyn has collaborated with scholars based in United States, Italy and China. Frequent co-authors include Anupama Munshi, L. Clifton Stephens, Marvette L. Hobbs, David Murray, Luka Milas, Clifton C. Ling, William C. Dewey, David Voehringer, Timothy J. McDonnell and John F. Kurland. Their work appears in journals such as Radiation Research, International Journal of Radiation Oncology*Biology*Physics, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact